Pacira Biosciences Inc has 11 Schedule 13D or 13G filings on record since 2025-08-08. 5 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Stated intent
Intent stated in Item 4 Doma Perpetual Capital Management LLC
The Reporting Persons sent a letter to the Board of Directors on November 10, 2025 (the "Letter"), which is attached hereto and has been or is being made public.From Item 4 of the SCHEDULE 13D/A filed 2025-11-10
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Doma Perpetual Capital Management LLC | 7.3% | 2,777,794 | SCHEDULE 13D/A, 2026-03-12 | 2026-03-11 |
| Vanguard Portfolio Management | 6.38% | 2,585,964 | SCHEDULE 13G, 2026-05-01 | 2026-03-31 |
| State Street Corporation | 5.2% | 2,059,977 | SCHEDULE 13G, 2026-08-07 | 2026-06-30 |
| Vanguard Capital Management | 5.15% | 2,088,291 | SCHEDULE 13G, 2026-05-01 | 2026-03-31 |
| Dimensional Fund Advisors LP | 5.1% | 2,060,597 | SCHEDULE 13G, 2026-04-09 | 2026-03-31 |
| Renaissance Technologies LLC | 4.98% | 2,138,201 | SCHEDULE 13G/A, 2025-11-13 | 2025-07-01 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-27 | 2026-03-13 |
Purpose of Transaction (Item 4)
Doma Perpetual Capital Management LLC
On March 11, 2026, Doma Master Fund submitted to the Issuer a notice (the "Notice") of its intent to nominate three directors to the Board of Directors of the Issuer (the "Board") at the Issuer's 2026 annual meeting of stockholders (the "Annual Meeting"). As of such date, Doma Master Fund intends to nominate Mr. de Armas, Christopher Dennis, and Oliver Benton Curtis III, as nominees (each a "Nominee" and collectively, the "Nominees") to be elected to the Board as directors at the Annual Meeting. Doma Master Fund stated in the Notice that it intends to solicit proxies in support of the Nominees' election to the Board in accordance with applicable law. The biographies of the Nominees may be found in the Press Release (as defined below), which is attached hereto as Exhibit 99.2. On March 11, 2026, DOMA issued a press release announcing the nomination of the Nominees to the Board, which press release was reissued on March 12, 2026, to correct certain inadvertent errors (the reissued press release, the "Press Release"). In the Press Release, DOMA called for Frank Lee, the Issuer's chief executive officer, to be replaced immediately, and stated that the Board should name an interim chief executive officer. In addition, DOMA stated that it believes electing the Nominees to the Board is critical to improving the Board's level of financial controls, sophistication and legal expertise, and would help develop increased management oversight at the Board level. DOMA further noted …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-03-12; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-08 | Doma Perpetual Capital Management LLC | 5.7% | SCHEDULE 13D |
| 2025-08-13 | Renaissance Technologies LLC | 5.34% | SCHEDULE 13G |
| 2025-11-10 | Doma Perpetual Capital Management LLC intent stated | 6.83% | SCHEDULE 13D/A |
| 2025-11-13 | Renaissance Technologies LLC | 4.98% | SCHEDULE 13G/A |
| 2026-01-02 | Doma Perpetual Capital Management LLC | 6.83% | SCHEDULE 13D/A |
| 2026-03-12 | Doma Perpetual Capital Management LLC | 7.3% | SCHEDULE 13D/A |
| 2026-03-27 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-04-09 | Dimensional Fund Advisors LP | 5.1% | SCHEDULE 13G |
| 2026-05-01 | Vanguard Capital Management | 5.15% | SCHEDULE 13G |
| 2026-05-01 | Vanguard Portfolio Management | 6.38% | SCHEDULE 13G |
| 2026-08-07 | State Street Corporation | 5.2% | SCHEDULE 13G |
Tools for this story
Each opens in a new tab, filled in for Pacira Biosciences Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.